STAT3 and non-small cell lung carcinoma: Collectively, we assumed that the APE1/IL‐6/STAT3 signalling participated in the modulation of Erlotinib resistance in NSCLCs, and we demonstrated shAPE1‐loaded RCSC‐EVs could reduce the resistance of NSCLC to Erlotinib.